Syndax Pharmaceuticals Inc
For the period ended Mar 31, 2026. Filed Apr 30, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed Apr 30, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Trading Arrangements
During the three months ended March 31, 2026, our directors and officers (as defined in Rule 16a-1 (f) under the Exchange Act)adopted orterminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement,” as defined in Regulation S-K Item 408 for the purchase or sale of our securities as set forth in the table below.
| Type of Trading Arrangement | |||||||
|---|---|---|---|---|---|---|---|
| Name and Position | Action | Adoption/Termination Date | Rule 10b5-1* | Non- Rule 10b5-1** | Total Shares of Common Stock to be Sold | Total Shares of Common Stock to be Purchased | Expiration Date |
| Dennis Podlesak, Director | Adoption | 12/15/2025 | X | 8,000 | 10/31/2026 | ||
| Michael A. Metzger Chief Executive Officer, Director | Adoption | 3/10/2026 | X | 182,375 | - | 12/15/2027 | |
| Nicholas Botwood, Head of R&D, Chief Medical Officer | Adoption | 3/11/2026 | X | 65,515 | - | 10/30/2026 | |
- Contract, instructions, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.
** “Non-Rule 10b5-1 trading arrangement” as defined in Item 408(c) of Regulation S-K under the Exchange Act.
1 Mr. Podlesak’s plan solely includes equity grants with expiration dates prior to October 31, 2026. The Company omitted inclusion of his plan adoption in its 12/31/2025 filing.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.